Literature DB >> 12355409

Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer.

Tatsuo Nakagawa1, Fumihiro Tanaka, Tetsuya Takata, Katsunari Matsuoka, Ryo Miyahara, Yosuke Otake, Kazuhiro Yanagihara, Masakazu Fukushimab, Hiromi Wada.   

Abstract

BACKGROUND AND OBJECTIVES: Dihydropyrimidine dehydrogenase (DPD) activity in tumor cells has been suggested to be one of the factors determining the effectiveness of 5-fluorouracil (5-FU). In the present study, we analyzed DPD expression in tumors and investigated retrospectively the relationship between the efficacy of UFT (Tegafur + Uracil) as adjuvant chemotherapy and DPD expression in nonsmall-cell lung cancer (NSCLC).
METHODS: DPD expression of 166 resected p-stage I NSCLC was examined immunohistochemically. Patients who were administered UFT alone as adjuvant therapy comprised the UFT group (n = 54), and those who underwent only surgery comprised the control group (n = 112). DPD expression was categorized as either high or low, according to intensity of staining.
RESULTS: DPD expression was high in 98 patients (59.0%) and low in 68 patients (41.0%). Patients with low-DPD tumors who were administered UFT had a significantly better prognosis than those who did not receive adjuvant treatment (P = 0.021). No significant difference was found between the two groups of patients with high-DPD tumors (P = 0.598).
CONCLUSIONS: DPD expression may predict the efficacy of UFT after surgery for p-stage I NSCLC. A prospective study is needed to confirm the role of DPD expression as a predictor of UFT efficacy. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12355409     DOI: 10.1002/jso.10137

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  4 in total

Review 1.  UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon/rectum, and breast): clinical evidence, mechanism of action, and future direction.

Authors:  Fumihiro Tanaka
Journal:  Surg Today       Date:  2007-10-25       Impact factor: 2.549

2.  Pharmacokinetic and Pharmacodynamic Analyses of 5-Fluorouracil in East-Asian Patients with Nasopharyngeal Carcinoma.

Authors:  Yuxiang Ma; Yuehao Lin; Benyan Zou; Wanli Liu; Yang Zhang; Liping Zhao; Yan Huang; Yunpeng Yang; Wenfeng Fang; Yuanyuan Zhao; Jin Sheng; Tao Qin; Zhihuang Hu; Salavatore J Salamone; Yunying Li; Li Zhang; Hongyun Zhao
Journal:  Clin Pharmacokinet       Date:  2016-10       Impact factor: 6.447

3.  Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT.

Authors:  J Nakano; C Huang; D Liu; D Masuya; T Nakashima; H Yokomise; M Ueno; H Wada; M Fukushima
Journal:  Br J Cancer       Date:  2006-08-01       Impact factor: 7.640

4.  High-dose oral tegafur-uracil maintenance therapy in patients with uterine cervical cancer.

Authors:  Isao Sakaguchi; Takeshi Motohara; Fumitaka Saito; Kiyomi Takaishi; Yukitoshi Fukumatsu; Toshimitsu Tohya; Saburo Shibata; Hiroyuki Mimori; Hironori Tashiro; Hidetaka Katabuchi
Journal:  J Gynecol Oncol       Date:  2015-02-17       Impact factor: 4.401

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.